Yili Chuanning Biotechnology Co. Ltd. A
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deace… Read more
Market Cap & Net Worth: Yili Chuanning Biotechnology Co. Ltd. A (301301)
Yili Chuanning Biotechnology Co. Ltd. A (SHE:301301) has a market capitalization of $3.48 Billion (CN¥25.56 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #8576 globally and #1644 in its home market, demonstrating a 4.47% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yili Chuanning Biotechnology Co. Ltd. A's stock price CN¥11.46 by its total outstanding shares 2230085000 (2.23 Billion).
Yili Chuanning Biotechnology Co. Ltd. A Market Cap History: 2022 to 2026
Yili Chuanning Biotechnology Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $2.65 Billion to $3.48 Billion (4.95% CAGR).
Index Memberships
Yili Chuanning Biotechnology Co. Ltd. A is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$625.44 Billion | 0.12% | #92 of 100 |
Weight: Yili Chuanning Biotechnology Co. Ltd. A's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Yili Chuanning Biotechnology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yili Chuanning Biotechnology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.63x
Yili Chuanning Biotechnology Co. Ltd. A's market cap is 0.63 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.57x
Yili Chuanning Biotechnology Co. Ltd. A's market cap is 2.57 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $2.65 Billion | $3.82 Billion | $411.52 Million | 0.69x | 6.45x |
| 2023 | $2.52 Billion | $4.82 Billion | $940.56 Million | 0.52x | 2.67x |
| 2024 | $3.60 Billion | $5.76 Billion | $1.40 Billion | 0.63x | 2.57x |
Competitor Companies of 301301 by Market Capitalization
Companies near Yili Chuanning Biotechnology Co. Ltd. A in the global market cap rankings as of March 18, 2026.
Key companies related to Yili Chuanning Biotechnology Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Yili Chuanning Biotechnology Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, Yili Chuanning Biotechnology Co. Ltd. A's market cap moved from $2.65 Billion to $ 3.48 Billion, with a yearly change of 4.95%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥3.48 Billion | +13.02% |
| 2025 | CN¥3.08 Billion | -14.50% |
| 2024 | CN¥3.60 Billion | +43.30% |
| 2023 | CN¥2.52 Billion | -5.23% |
| 2022 | CN¥2.65 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Yili Chuanning Biotechnology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.48 Billion USD |
| MoneyControl | $3.48 Billion USD |
| MarketWatch | $3.48 Billion USD |
| marketcap.company | $3.48 Billion USD |
| Reuters | $3.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.